Diana Peta-Ga English, MD
Obstetrics/Gynecology · Ft Lauderdale
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Holy Cross Hospital Inc · 299 clinicians in this group
Hospitals listed: Holy Cross Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. English’s office at (954) 229-6000 to ask if they take your plan before you enroll.
State licence records
1 licence
- Florida ME136881Medical Doctor · since 2018 · expires 2028-01-31ActiveNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
School, training and certification
2 placements
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- Gyn-Oncologycertified 2017
- Obstetrics And Gynecologycertified 2016
Education
- Univ. of the West Indies1999–2005
Residency and fellowship
- Yale University School of Medicine, OTHERNew Haven, CT · 2012–2015
- Univeristy of Miami/Jackson Memorial Hospital, OBSTETRICS AND GYNECOLOGYMiami, FL · 2008–2012
What else the board holds
Hospitals they may admit to
Where the clinician told their state board they may admit and treat patients.
- Stanford University School of Medicine · CA
Also licensed in
States the clinician told their board they are also licensed in. Only the states we check are verified.
California
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Holy Cross HospitalFt Lauderdale, FLAcute Care Hospital · Voluntary non-profit - Church · Has an emergency departmentPart of Trinity Health, which runs 105 hospitals in 16 statesPatients rate it 2 of 5 · 69% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.207, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0, Oct 2024 – Sep 2025
See every measure and the patient survey for Holy Cross Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 2 better, 8 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.207 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.72 (0.76 to 2.68) · 1,237 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.14 (0.83 to 1.44) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 131.84 (82.64 to 181.05) · 86 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.7 · 48 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 204 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.9 · 251 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.1 · 474 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.4 · 626 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.8 · 377 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4 · 4,342 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.38) · 7,857 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.08 to 0.46) · 8,283 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.4 (1.42 to 5.37) · 1,823 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.75 (0.19 to 3.32) · 694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.6 (1.14 to 4.06) · 1,673 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 14.54 (7.77 to 21.31) · 728 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.64 (2.91 to 10.37) · 664 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.66 (0.18 to 3.15) · 327 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.42 (0 to 1.02) · 6,197 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.3 · 182 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.63 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.499 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.2 · 412 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.1 · 831 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -4.3 · 269 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -11 · 561 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 6.8 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.5 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.6 (3.3 to 6.4) · 249 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.9 (7.8 to 12.5) · 249 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.2 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.4 · 74 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 334 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.5 (8.9 to 14.8) · 1,489 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 1,111 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,092 patients answered, 26% of those asked)
| Cleanliness | 2 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 1 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 62% |
| Nurses "always" communicated well | 70% |
| Doctors "always" communicated well | 70% |
| Staff "always" explained | 47% |
| Yes, staff "did" give patients this information | 79% |
| Yes, staff "did" give patients information about help after discharge | 79% |
| Doctors "always" explained things so they could understand | 64% |
| Doctors "always" listened carefully | 67% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 61% |
| Staff "always" explained new medications | 65% |
| Nurses "always" explained things so they could understand | 66% |
| Nurses "always" listened carefully | 66% |
| Nurses "always" treated them with courtesy and respect | 78% |
| "Always" quiet at night | 40% |
| "YES", patients would definitely recommend the hospital | 69% |
| Staff "always" explained possible side effects | 29% |
| Yes, staff "did" give patients information about possible symptoms | 79% |
Original Medicare doctor bills
$21,150
Medicare paid this office $21,150 for 77 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 33 | $3,368 | $80 |
| Long return visit (40+ min) | 13 | $1,595 | $106 |
| New patient visit (60+ min) | 11 | $1,508 | $137 |
Procedures Medicare counted
| Removal of the uterus | 1-10 | None |
Who their Medicare patients are
77 Original Medicare patients in 2024. Average age 72 · Also on Medicaid 20% · Health risk score 1.94. Sicker patients than 9 in 10 peers; the typical obstetrics & gynecology clinician is at 0.88.
Conditions among them: High blood pressure 75% · Cancer 42% · Chronic kidney disease 32% · Coronary heart disease 29% · Depression 27% · Diabetes 22% · Atrial fibrillation 22% · Heart failure 17% · COPD 17%.
The office billed $98,196, Medicare allowed $28,813 and paid $21,150; for 153 services of 28 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 77 | 153 | 72 | 1.94 | $98,196 | $21,150 |
| 2023 | 81 | 222 | 69 | 2.46 | $102,408 | $30,281 |
| 2022 | 71 | 237 | 70 | 2.35 | $95,840 | $26,720 |
| 2021 | 96 | 320 | 71 | 2.50 | $142,048 | $39,713 |
| 2020 | 77 | 238 | 70 | 2.91 | $125,340 | $34,012 |
| 2019 | 21 | 46 | 69 | 1.59 | $31,983 | $6,974 |
| 2018 | 103 | 220 | 70 | 2.67 | $194,041 | $26,475 |
| 2017 | 162 | 534 | 69 | 1.99 | $497,982 | $77,364 |
| 2016 | 116 | 437 | 69 | 2.02 | $329,024 | $56,405 |
| 2015 | 95 | 151 | 72 | 2.06 | $157,089 | $14,540 |
| 2014 | 224 | 322 | 71 | 1.73 | $305,755 | $29,145 |
| 2013 | 123 | 150 | 72 | 1.60 | $122,933 | $12,888 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| Long return visit (40+ min) | 50 | $12,138 | $106 |
| New patient visit (60+ min) | 25 | $3,549 | $142 |
2022: 2 services
| Long return visit (40+ min) | 39 | $9,656 | $105 |
| New patient visit (60+ min) | 16 | $2,141 | $134 |
2021: 5 services
| Long return visit (40+ min) | 37 | $11,420 | $115 |
| Return visit (30+ min) | 29 | $5,271 | $79 |
| New patient visit (60+ min) | 36 | $5,160 | $143 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 14 | $2,679 | $158 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 14 | $876 | $31 |
2020: 4 services
| Long return visit (40+ min) | 25 | $4,543 | $87 |
| New patient visit (60+ min) | 30 | $4,160 | $139 |
| Return visit (30+ min) | 22 | $2,937 | $64 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 12 | $891 | $33 |
2018: 3 services
| Short return visit (20+ min) | 33 | $1,707 | $40 |
| Short return visit (20+ min) | 30 | $1,567 | $46 |
| Short return visit | 11 | $207 | $17 |
2017: 12 services
| Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | 13 | $8,094 | $623 |
| Return visit (30+ min) | 44 | $4,174 | $64 |
| Short return visit (20+ min) | 46 | $3,048 | $44 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 25 | $2,507 | $34 |
| New patient visit (45+ min) | 18 | $2,017 | $112 |
| Return visit (30+ min) | 26 | $1,918 | $56 |
| New patient visit (60+ min) | 13 | $1,890 | $145 |
| New patient visit (45+ min) | 17 | $1,889 | $111 |
| Short return visit (20+ min) | 29 | $1,815 | $44 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 13 | $1,218 | $87 |
| Short return visit | 17 | $397 | $21 |
| Short return visit | 13 | $287 | $22 |
2016: 9 services
| Return visit (30+ min) | 32 | $4,187 | $66 |
| Return visit (30+ min) | 24 | $3,661 | $65 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 25 | $3,042 | $34 |
| New patient visit (45+ min) | 15 | $1,696 | $113 |
| New patient visit (45+ min) | 14 | $1,575 | $112 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 14 | $1,505 | $84 |
| New patient visit (60+ min) | 11 | $1,487 | $135 |
| Short return visit (20+ min) | 17 | $1,198 | $43 |
| Short return visit | 14 | $321 | $19 |
2015: 1 service
| Return visit (30+ min) | 62 | $3,360 | $52 |
2014: 4 services
| Long return visit (40+ min) | 97 | $7,644 | $72 |
| Return visit (30+ min) | 94 | $6,886 | $64 |
| Release of scar tissue at ureter | 13 | $1,689 | $130 |
| Short return visit | 12 | $275 | $21 |
2013: 2 services
| Return visit (30+ min) | 62 | $4,043 | $62 |
| Long return visit (40+ min) | 38 | $3,444 | $88 |
Medicaid work
$2,327 in 2024
Medicaid paid $2,327 for 41 billed services this clinician did in 2024, up to 18 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 41 | $2,327 |
| 2024 | 41 | 1 | 18 | $2,327 |
| 2023 | 960 | 7 | 37 | $22,897 |
| 2022 | 967 | 12 | 32 | $19,984 |
| 2021 | 61 | 1 | 18 | $4,762 |
| 2018 | 49 | 1 | 18 | $1,232 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 420 | $18,518 |
| OFF/OP EST MAY X REQ PHY/QHP | 53 | $4,379 |
| TOBACCO NON-USER | 158 | $0 |
| COLORECTAL CANCER SCREENING RESULTS DOC&REV | 57 | $0 |
| Bmi documented outside normal parameters, no follow-up plan documented, no reason given | 70 | $0 |
| Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 150 | $0 |
| Flu immunize no admin | 52 | $0 |
2022
| Long return visit (40+ min) | 274 | $13,889 |
| OFF/OP EST MAY X REQ PHY/QHP | 57 | $4,944 |
| Short return visit | 17 | $1,113 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 15 | $38 |
| TOBACCO NON-USER | 156 | $0 |
| COLORECTAL CANCER SCREENING RESULTS DOC&REV | 108 | $0 |
| Patient screened for tobacco use and received tobacco cessation intervention (counseling, pharmacotherapy, or both), if identified as a tobacco user (PV, CAD) | 18 | $0 |
| Bmi documented outside normal parameters, no follow-up plan documented, no reason given | 16 | $0 |
| Bmi is documented within normal parameters and no follow-up plan is required | 30 | $0 |
| Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 47 | $0 |
| Current list of medications not documented as obtained, updated, or reviewed by the eligible clinician, reason not given | 121 | $0 |
| Flu immunize no admin | 108 | $0 |
2021
| Short return visit | 61 | $4,762 |
2018
| Short return visit (20+ min) | 49 | $1,232 |
Drugs they prescribed that Part D paid
$295,539
Pharmacies billed $295,539 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 20% of their Part D prescriptions (58 of 298) in 2024. A higher opioid share than 9 in 10 peers; the typical obstetrics & gynecology clinician is at 0%.
267 generic and 31 brand-name prescriptions · $295,539 in drug cost · 19 antibiotic prescriptions to 11 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Lynparza | 13 | $182,725 | $14,056 |
| Prochlorperazine Maleate | 15 | $408 | $27 |
| Oxycodone | 45 | $277 | $6 |
| Ondansetron | 31 | $166 | $5 |
| Ibuprofen | 30 | $113 | $4 |
See all 6 drugs
| Lynparza | 13 | $182,725 | $14,056 |
| Prochlorperazine Maleate | 15 | $408 | $27 |
| Oxycodone | 45 | $277 | $6 |
| Ondansetron | 31 | $166 | $5 |
| Ibuprofen | 30 | $113 | $4 |
| Gabapentin | 11 | $75 | $7 |
Year by year
| 2024 | 298 | 92 | 20% (58) | 10% | $295,539 |
| 2023 | 761 | 108 | 39% (293) | None | $410,877 |
| 2022 | 519 | 84 | 40% (208) | 9% | $138,388 |
| 2021 | 575 | 115 | 33% (187) | 10% | $361,022 |
| 2020 | 408 | 105 | 27% (110) | 11% | $176,329 |
| 2019 | 79 | 25 | 23% (18) | None | $2,371 |
| 2018 | 158 | 45 | None | 13% | $60,875 |
| 2017 | 381 | 88 | None | 8% | $83,404 |
| 2016 | 403 | 77 | None | None | $61,348 |
| 2015 | 173 | 65 | 6% (11) | 11% | $20,136 |
| 2014 | 257 | 104 | 11% (27) | 14% | $18,792 |
| 2013 | 123 | 48 | 15% (19) | 24% | $8,418 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 17 drugs
| Lynparza | 23 | $265,158 | $11,529 |
| Ondansetron Odt | 27 | $3,085 | $114 |
| Oxycodone | 153 | $3,021 | $20 |
| Morphine Sulfate Er | 66 | $2,066 | $31 |
| Ramelteon | 18 | $1,908 | $106 |
| Morphine Sulfate | 19 | $873 | $46 |
| Gabapentin | 56 | $862 | $15 |
| Pregabalin | 20 | $753 | $38 |
| Hydromorphone | 23 | $500 | $22 |
| Lactulose | 31 | $489 | $16 |
| Duloxetine | 15 | $401 | $27 |
| Dicyclomine | 11 | $369 | $34 |
| Escitalopram | 31 | $364 | $12 |
| Prochlorperazine Maleate | 15 | $278 | $19 |
| Mirtazapine | 15 | $181 | $12 |
| Methadone | 12 | $164 | $14 |
| Lorazepam | 26 | $150 | $6 |
2022: 10 drugs
| Oxycodone | 104 | $2,608 | $25 |
| Morphine Sulfate Er | 49 | $2,142 | $44 |
| Gabapentin | 34 | $861 | $25 |
| Ondansetron Odt | 15 | $855 | $57 |
| Cyclobenzaprine | 12 | $564 | $47 |
| Morphine Sulfate | 16 | $562 | $35 |
| Mirtazapine | 19 | $555 | $29 |
| Escitalopram | 26 | $355 | $14 |
| Venlafaxine Hcl Er | 13 | $267 | $21 |
| Methadone | 16 | $188 | $12 |
2021: 13 drugs
| Lynparza | 20 | $263,588 | $13,179 |
| Oxycodone | 108 | $2,240 | $21 |
| Morphine Sulfate Er | 25 | $1,128 | $45 |
| Mirtazapine | 29 | $1,079 | $37 |
| Cyclobenzaprine | 13 | $1,070 | $82 |
| Ondansetron Odt | 15 | $905 | $60 |
| Oxycodone-Acetaminophen | 19 | $870 | $46 |
| Gabapentin | 54 | $856 | $16 |
| Dicyclomine | 14 | $452 | $32 |
| Escitalopram | 34 | $285 | $8 |
| Ibuprofen | 27 | $224 | $8 |
| Methadone | 14 | $151 | $11 |
| Sertraline | 11 | $136 | $12 |
2020: 9 drugs
| Lynparza | 11 | $160,613 | $14,601 |
| Enoxaparin | 12 | $3,597 | $300 |
| Megestrol Acetate | 12 | $2,757 | $230 |
| Oxycodone | 53 | $868 | $16 |
| Ondansetron Odt | 13 | $294 | $23 |
| Escitalopram | 21 | $226 | $11 |
| Ibuprofen | 25 | $182 | $7 |
| Gabapentin | 27 | $154 | $6 |
| Tramadol | 19 | $60 | $3 |
2018: 3 drugs
| Enoxaparin | 15 | $6,531 | $435 |
| Ondansetron | 14 | $255 | $18 |
| Letrozole | 15 | $232 | $15 |
2017: 12 drugs
| Enoxaparin | 17 | $5,406 | $318 |
| Megestrol Acetate | 11 | $1,031 | $94 |
| Polyethylene Glycol 3350 | 15 | $221 | $15 |
| Gabapentin | 16 | $213 | $13 |
| Ondansetron | 16 | $129 | $8 |
| Metformin | 12 | $91 | $8 |
| Ibu | 14 | $61 | $4 |
| Prochlorperazine Maleate | 11 | $60 | $5 |
| Metoclopramide | 13 | $58 | $4 |
| Lisinopril-Hydrochlorothiazide | 12 | $51 | $4 |
| Amlodipine Besylate | 12 | $40 | $3 |
| Famotidine | 11 | $26 | $2 |
2016: 10 drugs
| Enoxaparin | 14 | $3,866 | $276 |
| Megestrol Acetate | 15 | $909 | $61 |
| Glipizide-Metformin | 13 | $649 | $50 |
| Atorvastatin | 12 | $204 | $17 |
| Metoclopramide | 15 | $148 | $10 |
| Amlodipine Besylate | 11 | $92 | $8 |
| Ibuprofen | 18 | $92 | $5 |
| Losartan | 12 | $74 | $6 |
| Metformin | 16 | $71 | $4 |
| Lisinopril-Hydrochlorothiazide | 13 | $60 | $5 |
2015: 2 drugs
| Estrace | 14 | $2,895 | $207 |
| Prochlorperazine Maleate | 17 | $166 | $10 |
2014: 5 drugs
| Estrace | 19 | $3,215 | $169 |
| Nystatin | 12 | $220 | $18 |
| Gabapentin | 17 | $183 | $11 |
| Prochlorperazine Maleate | 15 | $167 | $11 |
| Levothyroxine | 12 | $148 | $12 |
2013: 1 drug
| Estradiol | 11 | $531 | $48 |
Money from drug and device companies
$1,326 in 2025
| 2025 | 5 | 8 | $1,088 | $1,326 |
| 2024 | 8 | 13 | $2,740 | $3,028 |
| 2023 | 4 | 10 | $700 | $1,041 |
| 2022 | 1 | 1 | None | $27 |
| 2021 | 2 | 5 | $1,395 | $1,579 |
| 2019 | 2 | 17 | $13,675 | $16,397 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| GlaxoSmithKline | Jemperli | $1,104 | 2 payments
|
| Abbvie | Elahere | $168 | 3 payments
|
| Myriad Genetic Laboratories | Myrisk | $21 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $17 | 1 payment
|
| Corcept Therapeutics | Korlym | $16 | 1 payment
|
See all 8 published payments
| Abbvie | Meals · 2025-12-16 | Elahere | $27 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-21 | Lynparza | $17 |
| GlaxoSmithKline | Consulting · 2025-10-10 | Jemperli | $1,088 |
| GlaxoSmithKline | Meals · 2025-08-06 | Jemperli | $16 |
| Corcept Therapeutics | Meals · 2025-07-29 | Korlym | $16 |
| Abbvie | Meals · 2025-06-14 | Elahere | $127 |
| Myriad Genetic Laboratories | Meals · 2025-04-09 | Myrisk | $21 |
| Abbvie | Meals · 2025-03-11 | Elahere | $14 |
See earlier years (2024, 2023, 2022, 2021, 2019)
2024: $3,028
| AstraZeneca Pharmaceuticals LP | None | $2,740 | 1 payment
|
| Myriad Genetic Laboratories | Precisetumor | $75 | 3 payments
|
| Novartis Pharmaceuticals | Kisqali | $54 | 2 payments
|
| Eisai | Lenvima | $50 | 2 payments
|
| GlaxoSmithKline | Jemperli | $48 | 2 payments
|
| Astellas Pharma US | Veozah | $27 | 1 payment
|
| Daiichi Sankyo | Enhertu | $18 | 1 payment
|
| Abbvie | Elahere | $16 | 1 payment
|
2023: $1,041
| Medtronic | Synchromedii | $718 | 2 payments
|
| Eisai | Lenvima | $159 | 4 payments
|
| GlaxoSmithKline | Jemperli | $124 | 2 payments
|
| Ethicon US | Stratafix | $40 | 1 payment
|
2022: $27
| Ethicon US | Dermabond Prineo | $27 | 1 payment
|
2021: $1,579
| Medtronic | None | $1,395 | 2 payments
|
| GlaxoSmithKline | Zejula | $184 | 3 payments
|
2019: $16,397
| AstraZeneca Pharmaceuticals LP | Lynparza | $16,272 | 16 payments
|
| Clovis Oncology | Rubraca | $125 | 1 payment
|
Professional record
- NPI
- 1932357241
- Licence
- FL ME136881Florida ME136881: Active
- Gender
- Female
More record details
- Sole proprietor
- No
- Medicaid ID
- FL 103143200
- Taxonomy
- Federal specialty code 207V00000X (207V00000X)
- Mailing address
- Po Box 917770, Orlando, FL, 32891
- NPI first listed
- 2008-08-29
- NPI last updated
- 2022-01-13
- NPI record certified
- 2022-01-13
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 300 Pasteur Dr, Stanford, CA, 94305
This office lists an electronic records connection.